Myeloproliferative disorder therapy: assessment and management of adverse events--a dermatologist's perspective.
Hematol Oncol
; 27 Suppl 1: 11-3, 2009 Jun.
Article
en En
| MEDLINE
| ID: mdl-19468982
ABSTRACT
Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of these alter quality of life. Hydroxyurea has been shown to induce a variety of cutaneous adverse reactions ranging from benign effects such as hyperpigmentation to more severe leg ulcers and squamous cell carcinomas. Herein, we discuss the importance of undertaking regular physical examinations in order to identify and treat cutaneous manifestations early in their course.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Dermatología
/
Trastornos Mieloproliferativos
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Hematol Oncol
Año:
2009
Tipo del documento:
Article
País de afiliación:
Francia